Recursion Pharmaceuticals, Inc. (RXRX) Tops Q1 EPS by 1c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $12.13 million versus the consensus estimate of $12.97 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters